Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Till, Brian G
[Clear All Filters]
2015
Cowan AJ
,
Stevenson PA
,
Cassaday RD
,
Graf SA
,
Fromm JR
,
Wu D
,
Holmberg LA
,
Till BG
,
Chauncey TR
,
Smith SD
, et al.
Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission.
Biol Blood Marrow Transplant. 2015.
PubMed
Google Scholar
2018
Till BG
.
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Curr Treat Options Oncol. 2018;19(9):45.
PubMed
Google Scholar
2021
Lynch RC
,
Cassaday RD
,
Smith SD
,
Fromm JR
,
Cowan AJ
,
Warren EH
,
Shadman MS
,
Shustov A
,
Till BG
,
Ujjani CS
, et al.
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lancet Haematol. 2021;8(8):e562-e571.
PubMed
Google Scholar
2023
Cowan AJ
,
Pont MJ
,
Sather BD
,
Turtle CJ
,
Till BG
,
Libby EN
,
Coffey DG
,
Tuazon SA
,
Wood B
,
Gooley T
, et al.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Lancet Oncol. 2023;24(7):811-822.
PubMed
Google Scholar
2024
Krakow EF
,
Brault M
,
Summers C
,
Cunningham TM
,
Biernacki MA
,
R Black G
,
Woodward KBlake
,
Vartanian N
,
Kanaan SB
,
Yeh AC
, et al.
HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Blood. 2024.
PubMed
Google Scholar